"
Team:WITS-CSIR SA/Project/Achievements
From 2011.igem.org
| Line 93: | Line 93: | ||
<div data-dojo-type="dijit.layout.ContentPane" data-dojo-props="region: 'top'" class="top"> | <div data-dojo-type="dijit.layout.ContentPane" data-dojo-props="region: 'top'" class="top"> | ||
<a href="https://2011.igem.org/Team:WITS-CSIR_SA"> | <a href="https://2011.igem.org/Team:WITS-CSIR_SA"> | ||
| - | <img src="https://static.igem.org/mediawiki/2011/ | + | <img src="https://static.igem.org/mediawiki/2011/5/56/Wits_Logo_Biotweet.gif" alt="Biotweet" height="80px" |
style="float: left; margin-bottom: 10px; border: none;" /> | style="float: left; margin-bottom: 10px; border: none;" /> | ||
</a><a href="https://2011.igem.org/Main_Page" target="_blank"> | </a><a href="https://2011.igem.org/Main_Page" target="_blank"> | ||
Revision as of 17:20, 6 October 2011
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
1) We have submitted 11 biobrick parts to the Registry of Standard Biological Parts. Three new biobrick parts representing our “favourite” biobricks, BBa_K537001, BBa_K537002 and BBa_K537003, have been fully characterized.
2) We are the first team to characterize the function of two different types of theophylline-responsive riboswitches, and this was achieved for two separate coding sequences. These riboswitch designs are improvements over previously-developed iGEM riboswitches.
3) Theophylline-response riboswitch 2 (thRS2-CheZ, BBa_K537002) was capable of significantly higher activation than Theophylline-response riboswitch 1 (thRS1, BBa_K537001) when expressing motility factor CheZ (37-fold vs 4-fold). Moreover, thRS2 showed 6-fold improved motility function over thRS1 and 1-fold increased chemotactic sensitivity to theophylline.
4) Theophylline-responsive riboswitch 2-CheZ (BBa_K537002) represents an ideal biobrick for N-terminal fusion to proteins of interest for theophylline-activated messenger activity. This part could have numerous advantages in several other synthetic biology applications.
